A detailed history of Hartford Investment Management CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hartford Investment Management CO holds 16,250 shares of VRTX stock, worth $6.67 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
16,250
Previous 16,534 1.72%
Holding current value
$6.67 Million
Previous $7.75 Million 2.48%
% of portfolio
0.25%
Previous 0.27%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$460.0 - $505.78 $130,640 - $143,641
-284 Reduced 1.72%
16,250 $7.56 Million
Q2 2024

Aug 01, 2024

SELL
$392.81 - $485.53 $47,530 - $58,749
-121 Reduced 0.73%
16,534 $7.75 Million
Q1 2024

Apr 17, 2024

SELL
$407.69 - $446.08 $285,790 - $312,702
-701 Reduced 4.04%
16,655 $6.96 Million
Q4 2023

Jan 23, 2024

SELL
$343.0 - $410.68 $122,108 - $146,202
-356 Reduced 2.01%
17,356 $7.06 Million
Q3 2023

Oct 16, 2023

SELL
$338.18 - $362.46 $158,606 - $169,993
-469 Reduced 2.58%
17,712 $6.16 Million
Q2 2023

Jul 19, 2023

SELL
$314.42 - $351.91 $1.09 Million - $1.22 Million
-3,476 Reduced 16.05%
18,181 $6.4 Million
Q1 2023

May 09, 2023

SELL
$283.23 - $323.1 $735,831 - $839,413
-2,598 Reduced 10.71%
21,657 $6.82 Million
Q4 2022

Jan 20, 2023

SELL
$285.76 - $321.48 $25,718 - $28,933
-90 Reduced 0.37%
24,255 $7 Million
Q3 2022

Nov 02, 2022

SELL
$273.83 - $305.53 $43,538 - $48,579
-159 Reduced 0.65%
24,345 $7.05 Million
Q2 2022

Jul 22, 2022

BUY
$234.96 - $292.55 $98,683 - $122,871
420 Added 1.74%
24,504 $6.91 Million
Q1 2022

Apr 20, 2022

SELL
$221.42 - $260.97 $379,071 - $446,780
-1,712 Reduced 6.64%
24,084 $6.29 Million
Q4 2021

Feb 02, 2022

BUY
$177.01 - $223.45 $284,101 - $358,637
1,605 Added 6.63%
25,796 $5.67 Million
Q3 2021

Nov 01, 2021

SELL
$181.39 - $202.99 $554,690 - $620,743
-3,058 Reduced 11.22%
24,191 $4.39 Million
Q2 2021

Jul 29, 2021

SELL
$187.49 - $221.1 $212,801 - $250,948
-1,135 Reduced 4.0%
27,249 $5.49 Million
Q1 2021

Apr 21, 2021

SELL
$207.02 - $241.31 $264,985 - $308,876
-1,280 Reduced 4.31%
28,384 $6.1 Million
Q4 2020

Feb 01, 2021

BUY
$207.01 - $276.09 $516,489 - $688,844
2,495 Added 9.18%
29,664 $7.01 Million
Q3 2020

Oct 29, 2020

SELL
$255.65 - $303.1 $237,754 - $281,883
-930 Reduced 3.31%
27,169 $7.39 Million
Q2 2020

Aug 04, 2020

BUY
$225.48 - $295.8 $47,801 - $62,709
212 Added 0.76%
28,099 $8.16 Million
Q1 2020

Apr 24, 2020

BUY
$199.77 - $247.81 $201,567 - $250,040
1,009 Added 3.75%
27,887 $6.64 Million
Q4 2019

Jan 29, 2020

SELL
$166.71 - $223.91 $110,695 - $148,676
-664 Reduced 2.41%
26,878 $5.89 Million
Q3 2019

Oct 28, 2019

SELL
$166.23 - $187.09 $43,552 - $49,017
-262 Reduced 0.94%
27,542 $4.67 Million
Q2 2019

Jul 25, 2019

BUY
$164.61 - $190.37 $28,477 - $32,934
173 Added 0.63%
27,804 $5.1 Million
Q1 2019

Apr 29, 2019

SELL
$163.73 - $194.7 $272,119 - $323,591
-1,662 Reduced 5.67%
27,631 $5.08 Million
Q4 2018

Feb 04, 2019

BUY
$151.91 - $192.21 $140,061 - $177,217
922 Added 3.25%
29,293 $4.85 Million
Q3 2018

Nov 08, 2018

SELL
$167.73 - $192.74 $278,431 - $319,948
-1,660 Reduced 5.53%
28,371 $5.47 Million
Q2 2018

Jul 19, 2018

SELL
$145.72 - $169.96 $2.83 Million - $3.3 Million
-19,440 Reduced 39.3%
30,031 $5.1 Million
Q1 2018

Apr 24, 2018

SELL
$151.6 - $177.13 $572,593 - $669,020
-3,777 Reduced 7.09%
49,471 $8.06 Million
Q4 2017

Feb 12, 2018

SELL
$137.28 - $155.55 $111,883 - $126,773
-815 Reduced 1.51%
53,248 $7.98 Million
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $8.01 Million - $8.77 Million
54,063
54,063 $8.22 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hartford Investment Management CO Portfolio

Follow Hartford Investment Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hartford Investment Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Hartford Investment Management CO with notifications on news.